HIV, lenacapavir and Data

Reformulation of HIV prevention drug lenacapavir makes it last for a year
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year. In their paper published in The Lancet journal,
GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive
Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir. Lenacapavir is a novel, once-yearly injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP).
Gilead presents data for once-yearly lenacapavir for HIV prevention
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
Gilead posts early Phase 1 data for once-yearly HIV PrEP therapy
Gilead (NASDAQ:GILD) on Tuesday announced encouraging initial data from an ongoing Phase 1 trial for lenacapavir, an intramuscular injection given as two once-yearly formulations for pre-exposure prophylaxis (PrEP) in HIV prevention.
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
(Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP).
MIT Technology Review10h
This annual shot might protect against HIV infections
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
PharmExec11h
Real-World Data Demonstrates Efficacy of Apretude and Cabenuva in HIV Prevention, Treatment
New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...
Montgomery Advertiser on MSN12h
Alabama still fighting HIV: 'In the South is where we have the majority of the problems':
Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...
The Lancet2d
Prevention and control of HPV-related cancers in people living with HIV
The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...
The American Journal of Managed Care1d
Bridging Gaps in HIV Care Through Pharmacy-Based Solutions
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center, collaborates with researchers from the Kenya Medical Research Institute ...
Study highlights gaps in HPV-related cancer prevention for people living with HIV
A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people ...
UNAIDS3h
Impact of US funding cuts on HIV programmes in Ethiopia
Human rights, key and vulnerable populations Ethiopia received PEPFAR funding for work on stigma, discrimination and enabling legal environments. As a result of the USG stop-work order, all programmes ...
The American Journal of Managed Care2d
Couples Counseling Key to HIV Prevention and Maternal Care
Lynae Darbes, PhD, presented research on the effectiveness of a home-based intervention for HIV prevention among couples ...
News Medical on MSN2d
Gaps in HPV cancer screening and prevention identified for people living with HIV
A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities.
STAT1d
HIV self-testing is easy, effective — and underutilized
HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.